CYFRA 21-1 Tumor Marker: Why It Matters in Lung Cancer, Especially Squamous Cell Carcinoma
CYFRA 21-1 Tumor Marker: Why It Matters in Lung Cancer, Especially Squamous Cell Carcinoma
Tumor markers play an important supportive role in the diagnosis and follow-up of lung cancer. Among them, CYFRA 21-1 (Cytokeratin 19 fragment) is known for its high specificity in non–small cell lung cancer (NSCLC)—particularly squamous cell carcinoma (SCC).
In this article, we will review the biological background of CYFRA 21-1, factors associated with its elevation, its relationship with cancer staging, and key points to consider when interpreting results.
🔬 1. What Is CYFRA 21-1?
CYFRA 21-1 is a fragment of cytokeratin 19, a structural intermediate-filament protein found in epithelial cells.
When epithelial cells undergo damage, necrosis, or tumor-related destruction, cytokeratin 19 is broken down and released into the bloodstream.
This is why higher CYFRA 21-1 levels generally reflect:
- Increased tumor burden
- Greater tumor necrosis
- More advanced disease progression
🫁 2. Clinical Significance of CYFRA 21-1 in Lung Cancer
✔ 1) Most useful in non–small cell lung cancer—especially squamous cell carcinoma
Multiple studies consistently show:
- Highest sensitivity in squamous cell carcinoma (SCC)
- Moderate elevation in adenocarcinoma
- Higher levels in SCC even at the same stage of disease
Thus, CYFRA 21-1 serves as a valuable biomarker for SCC within the NSCLC group.
✔ 2) Correlation with cancer stage
CYFRA 21-1 levels increase as cancer advances:
| Stage | Likelihood of Elevation | Interpretation |
|---|---|---|
| Stage I | Low or normal | Limited sensitivity in early disease |
| Stage II–III | Moderate increase | Lymph node involvement or local invasion |
| Stage IV | High levels | Increased tumor burden and distant metastasis |
CYFRA 21-1 is not ideal for early detection, but it becomes increasingly informative as the disease progresses.
🧪 3. Causes of Elevated CYFRA 21-1
🔼 1) Lung cancer–related causes
- Squamous cell carcinoma (strongest association)
- Adenocarcinoma
- Large cell carcinoma
- Advanced or metastatic NSCLC
🔼 2) Non-cancer causes
Because it reflects epithelial cell injury, CYFRA 21-1 can also rise in benign conditions:
- Chronic liver disease (hepatitis, cirrhosis)
- Renal failure (reduced clearance)
- Pulmonary infections (pneumonia, tuberculosis)
- Inflammatory lung diseases
- Smoking (mild influence)
Thus, CYFRA 21-1 must always be interpreted with clinical context, radiologic findings, and other markers such as CEA, NSE, or SCC antigen.
📉 4. Useful for Monitoring Treatment Response
CYFRA 21-1 is highly valuable in follow-up:
- Decrease after treatment → good response
- Persistent elevation or re-elevation → possible recurrence or progression
This is especially helpful in squamous cell carcinoma, where several studies emphasize its prognostic relevance.
⚠ 5. Key Points to Consider in Interpretation
- Low sensitivity in early-stage lung cancer → not suitable for screening
- May increase in infections, inflammation, or renal dysfunction
- Normal levels do not rule out lung cancer
- Higher specificity for SCC, but elevation also possible in adenocarcinoma
Ultimately, CYFRA 21-1 serves as a supportive biomarker—not a standalone diagnostic tool.
Its greatest value lies in assessing tumor burden, prognosis, and treatment response.
📚 References
- Molina R, et al. Tumor markers in lung cancer: CYFRA 21-1 in squamous cell carcinoma. Lung Cancer.
- Stieber P, et al. CYFRA 21-1: Biological background and clinical utility. Clinical Chemistry and Laboratory Medicine.
- Pujol JL, et al. CYFRA 21-1 as a prognostic marker in NSCLC. European Journal of Cancer.
- Holdenrieder S, et al. Biomarkers and their role in early detection and monitoring of lung cancer. Clinical Lung Cancer.
- NCCN Guidelines: Non–Small Cell Lung Cancer.
- Barlesi F, et al. CYFRA 21-1 testing in NSCLC: Correlation with stage and outcome.